EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders

NEW YORK, Nov. 29, 2022

Class Period: March 10, 2021 to October 4, 2022
Lead Plaintiff Deadline: January 9, 2023
No obligation or cost to you.

Learn more about your recoverable losses in EIGR:
https://www.kleinstocklaw.com/pslra-1/eiger-biopharmaceuticals-class-action-submission-form?id=34080&from=4

Eiger BioPharmaceuticals, Inc. NEWS - EIGR NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Eiger you have until January 9, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Eiger securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.